- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
More ▼
Key statistics
On Thursday, Arcturus Therapeutics Holdings Inc (ARCT:NMQ) closed at 26.17, 49.37% above the 52 week low of 17.52 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.09 |
---|---|
High | 26.80 |
Low | 25.41 |
Bid | 25.32 |
Offer | 28.81 |
Previous close | 26.98 |
Average volume | 469.00k |
---|---|
Shares outstanding | 26.92m |
Free float | 24.56m |
P/E (TTM) | -- |
Market cap | 726.17m USD |
EPS (TTM) | -1.16 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼